
23 Feb PDC*line Pharma
Eric Halioua, Ph.D., CEO
April 16 | 2:00pm | Salone dei Cavalieri, Section 2
Belgium
(Private)
PDC*line Pharma is a Belgian-French biotech company that is developing a novel class of off-the-shelf cancer immunotherapies based on a proprietary Plasmacytoid Dendritic Cell line (PDC*line) pre-loaded with peptides that are derived from target tumor antigens. Based on a robust preclinical package and a first-in-human phase Ib feasibility study in melanoma, PDC*line Pharma is focusing on lung cancer with a new candidate in phase I/II clinical trial (PDC*lung) and neoantigens (PDC*Neo). PDC*line Pharma comprises a team of 42 highly skilled professionals based in Liège (Belgium) and Grenoble (France) and has raised more than €61M in equity and non-dilutive funding.